

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/970,154	10/04/2001	Toyohide Shinkawa	249-201	9598
7590 07/01/2004			EXAMINER	
NIXON & VANDERHYE P.C.			SAUNDERS, DAVID A	
8th Floor 1100 North Glebe Road			ART UNIT	PAPER NUMBER
Arlington, VA 22201			1644	
		•	DATE MAN ED 05/01/200	

DATE MAILED: 07/01/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	970,154 SHINKAWA etcl
Office Action Summary	Examiner Group Art Unit
—The MAILING DATE of this communication app	ears on the cover sheet beneath the correspondence address—
Period for Reply	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET OF THIS COMMUNICATION.	TO EXPIREMONTH(S) FROM THE MAILING DATE
from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a  - If NO period for reply is specified above, such period shall, by defa	R 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS a reply within the statutory minimum of thirty (30) days will be considered timely. ult, expire SIX (6) MONTHS from the mailing date of this communication . latute, cause the application to become ABANDONED (35 U.S.C. § 133).
Status	
☐ Responsive to communication(s) filed on	· · · · · · · · · · · · · · · · · · ·
☐ This action is <b>FINAL</b> .	
☐ Since this application is in condition for allowance exce accordance with the practice under <i>Ex parte Quayle</i> , 1	ept for formal matters, <b>prosecution as to the merits is closed</b> in 935 C.D. 1 1; 453 O.G. 213.
Disposition of Claims	
(b Claim(s) 1-2-1	is/are pending in the application.
	is/are withdrawn from consideration.
☐ Claim(s)	
□ Claim(s)	
	is/are objected to.
Claim(s) 1-2-1	are subject to restriction or election requirement.
Amplication Denous	•
Application Papers	
☐ See the attached Notice of Draftsperson's Patent Drav	
☐ See the attached Notice of Draftsperson's Patent Drav	is □ approved □ disapproved.
☐ The proposed drawing correction, filed on is/are obj	is □ approved □ disapproved.
<ul> <li>□ See the attached Notice of Draftsperson's Patent Drave</li> <li>□ The proposed drawing correction, filed on</li></ul>	is □ approved □ disapproved. ected to by the Examiner.
<ul> <li>□ See the attached Notice of Draftsperson's Patent Draven</li> <li>□ The proposed drawing correction, filed on</li></ul>	is □ approved □ disapproved. ected to by the Examiner.
☐ See the attached Notice of Draftsperson's Patent Drav ☐ The proposed drawing correction, filed on	is □ approved □ disapproved. ected to by the Examiner.
<ul> <li>□ See the attached Notice of Draftsperson's Patent Draven</li> <li>□ The proposed drawing correction, filed on</li></ul>	is □ approved □ disapproved. ected to by the Examiner.  under 35 U.S.C. § 11 9(a)-(d).
<ul> <li>□ See the attached Notice of Draftsperson's Patent Draven</li> <li>□ The proposed drawing correction, filed on</li></ul>	is approved disapproved. ected to by the Examiner.  under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been
□ See the attached Notice of Draftsperson's Patent Drav □ The proposed drawing correction, filed on	is approved disapproved. ected to by the Examiner.  under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been
□ See the attached Notice of Draftsperson's Patent Drav □ The proposed drawing correction, filed on	is approved disapproved. ected to by the Examiner.  under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been  her) nternational Bureau (PCT Rule 1 7.2(a)).
□ See the attached Notice of Draftsperson's Patent Drav □ The proposed drawing correction, filed on	is approved disapproved. ected to by the Examiner.  under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been  her) nternational Bureau (PCT Rule 1 7.2(a)).
□ See the attached Notice of Draftsperson's Patent Drav □ The proposed drawing correction, filed on	is approved disapproved. ected to by the Examiner.  under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been  hber) nternational Bureau (PCT Rule 1 7.2(a)).
□ See the attached Notice of Draftsperson's Patent Drav □ The proposed drawing correction, filed on □ The drawing(s) filed on □ The specification is objected to by the Examiner. □ The oath or declaration is objected to by the Examiner  Priority under 35 U.S.C. § 119 (a)-(d) □ Acknowledgment is made of a claim for foreign priority □ All □ Some* □ None of the CERTIFIED copies □ received. □ received in Application No. (Series Code/Serial Nur □ received in this national stage application from the I *Certified copies not received:  Attachment(s)	is approved disapproved. ected to by the Examiner.  under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been  hber)  nternational Bureau (PCT Rule 1 7.2(a)).

Application/Control Number: 09/970,154

Art Unit: 1617

The amendment of 6/10/02 has been entered. Claims 1-21 are pending and subject to restriction.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-17, drawn to various processes for antibody preparation via affinity purification/hydrophobic chromatography, classified in class 530, subclass 413 and 415.
- II. Claims 18-20, drawn to medicaments containing antibody, classified in class 424, subclass 130.1+.
- III. Claim 21, drawn to diagnostic methods for disease, classified in class 435, subclass 7.1+ and class 436, subclass 501+.

The inventions are distinct, each from the other because:

Inventions I and II are related as a process making and product made. The inventions are distinct if either or both the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process. MPEP 806.05 (f). In the instant case, product could have been obtained by other methods. Numerous art known methods of preparing immunoglobu, for therapeutic use employ hydrophobic interaction chromatography as at least one of the steps of purification; since applicant's claims set forth no physical/chemical features of the composition, it is reasonably considered that the composition obtained would not be distinguishable from that obtained by other known methods.

Application/Control Number: 09/970,154

Art Unit: 1617

Inventions I (or II) and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the invention of claim 21 is so vague that it does not even require the use of any antibody prepared by the method of Group I, or prepared by any other method; all that is required is that something with carbohydrate binding affinity (e.g. a lectin) be used in a detection process—e.g. to bind to unpurified antibody in a serum sample. Further the lectin need not even be used to bind an antibody; the lectin could be used to detect cell surface glycoproteins from cells, for example.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/970,154

Art Unit: 1617

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David A. Saunders, PhD whose telephone number is 571-272-0849. The examiner can normally be reached on Monday-Thursday from 8:00a.m to 5:30 p.m. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan, can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Saunders/tgd

June 24, 2004

Queil a Sacenders DAVID SAUNDERS
PRIMARY EXAMINER
ART UNIT 182/644